Hostname: page-component-848d4c4894-x5gtn Total loading time: 0 Render date: 2024-05-22T09:56:05.636Z Has data issue: false hasContentIssue false
  • English
  • Français

The impact of treatment with antidepressants on HBA1c- and LDL levels in type 2 diabetes: A real-world within-subject study

Published online by Cambridge University Press:  13 August 2021

C. Rohde ,
R.W. Thomsen  and
S. Østergaard
C. Rohde*
Affiliation:
Department Of Affective Disorders, Aarhus University Hospital, Århus N, Denmark
R.W. Thomsen
Affiliation:
Department Of Clinical Epidemiology, Aarhus University Hospital, Århus N, Denmark Department Of Clinical Medicine, Aarhus University Hospital, Århus N, Denmark
S. Østergaard
Affiliation:
Department Of Affective Disorders, Aarhus University Hospital, Århus N, Denmark Department Of Clinical Medicine, Aarhus University, Aarhus, Denmark
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

With regard to glycemic control in type 2 diabetes (T2D), treatment with antidepressant drugs is a double-edged sword. Real-world, population-based data on the impact of antidepressant treatment on glycemic control in T2D is absent from the literature.

Objectives

To estimate the impact of treatment initiation or termination with an antidepressant on HbA1c levels in individuals with T2D.

Methods

Population-based, within-subject, study design examining HbA1c levels in the 16 months leading up to - and the 16 months following - antidepressant treatment initiation or termination, respectively. All individuals with newly developed T2D between 1 January 2000 and 31 October 2016 were identified. Study population 1 consisted of individuals that initiated antidepressant treatment after incident T2D and age- and sex matched individuals with T2D and without antidepressant treatment. Study population 2 consisted of individuals with prevalent antidepressant use at the time of incident T2D, who terminated antidepressant treatment during follow-up, and age- and sex matched individuals with T2D and without antidepressant treatment.

Results

Antidepressant treatment initiation was associated with a decrease in HbA1c levels (7.05% to 6.89%). The age- and sex matched individuals did not have a change in mean HbA1c levels after the matched date. Antidepressant treatment termination was associated with a decrease in HbA1c levels (7.05% to 6.73%). Age- and sex matched individuals did not see a change in HbA1c levels after the matched date.

Conclusions

These findings suggest that antidepressant treatment initiation is not associated with adverse effects with regard to glycemic control in T2D. Rather, the data are indicative of a beneficial effect.

Conflict of interest

Aarhus University funded the study. CR was supported by the Danish Diabetes Academy, funded by the Novo Nordisk Foundation, grant number NNF17SA0031406. The funders had no role in the study design, data analysis, interpretation of data, or writing of the

Keywords

DepressionType 2 DiabetesGlycemic controlPopulation-based study
Type
Abstract
Information
European Psychiatry , Volume 64 , Special Issue S1: Abstracts of the 29th European Congress of Psychiatry , April 2021 , pp. S235 - S236
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.